This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
ATH Technologies (E)
Simons, Robert L.; Packard, JenniferCase HBS-117017-EStrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Merck: Managing Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-109084-EStarting at €5.74
-
ATH Technologies (E) (Spanish version)
Simons, Robert L.; Packard, JenniferCase HBS-118S07StrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74
-
Argentina: The convertibility programme
Fracchia L. E.; Gual, JordiCase ASE-370-EEconomicsStarting at €8.20
-
Argentina: El programa de convertibilidad
Fracchia L. E.; Gual, JordiCase ASE-370EconomicsEste caso analiza la implantación del programa de convertibilidad en la economía argentina. Se discute el período 1991-1996 analizando el impacto del programa tanto en la economía real como en la situación financiera del país.Starting at €8.20
-
Celulo Ltd.
Perote J.; Pastor, Alfredo; Gual, JordiCase ASE-408-EEconomicsThis is a revised and abridged version of the case ASE-375-E The external effects problem.Starting at €8.20
-
Cleanriver Town
Perote J.; Pastor, Alfredo; Gual, JordiCase ASE-407-EEconomicsThis is a revised and abridged version of the case ASE-374-E Public goods.Starting at €8.20
-
C3.ai-Driven to Succeed
Simons, Robert L.; Gonzalez, GeorgeCase HBS-119004-EStrategyCEO Tom Siebel navigates his artificial intelligence (ai) startup through a series of pivots, market expansions, and even an elephant attack to become a leading platform ad service provider. The case describes his unusual management approach emphasizing eStarting at €8.20
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20